ENTYVIO® (Vedolizumab) is an anti-inflammatory drug used to treat Inflammatory Bowel Diseases.

ENTYVIO® is manufactured by Takeda.

Administration and Dosage:

Administration of ENTYVIO® follows an induction regimen of 3 intravenous infusions at 0, 2, and 6 weeks followed by a maintenance infusion, once every 8 weeks.


ENTYVIO® is indicated to treat:

  • Crohn’s Disease
  • Ulcerative Colitis

Common Side Effects:

The more common side effects of ENTYVIO® include infusion-related and serious allergic reactions, infections, Progressive Multifocal Leukoencephalopathy (PML), and liver problems.

More information:

Please read the full Prescribing Information and Medication Guide for ENTYVIO® and discuss any questions you have with your doctor.


We are happy to help!